Multiple reports say President Donald Trump plans to fire FDA Commissioner Marty Makary, though the plan is not finalized. If executed, the move would end Makary’s tenure, which has included controversy around vaccine policy positions and broader scrutiny tied to regulatory consistency. The reporting also points to heightened agency turnover and concerns voiced by former FDA leadership about expertise loss and political influence affecting decision-making. For industry stakeholders, uncertainty in FDA leadership can affect perceptions around review timelines, policy emphasis areas, and stakeholder engagement. In parallel, the story notes that the FDA authorized 45 types of e-cigarettes recently, an additional point cited in the context of policy tensions. The net effect for biotech is a reminder that executive transitions can occur quickly and can reverberate through centers including CDER and CBER. The key watchpoint is whether an acting commissioner is named and whether leadership change is accompanied by any immediate shifts in regulatory priorities or review operating procedures.